Is MBX Biosciences, Inc. Common Stock (MBX) a Buy, Sell, or Hold?
NASDAQ : MBX
MBX Biosciences, Inc. Common Stock
$62 USD
-$1.57 (-2.47%)
- Volume
- 500.94K
- Average Volume
- 857.07K
- Market Capitalization
- $2.95B
- P/E Ratio
- -28.18
- Dividend Yield
- 0.00%
- Price Target
- $70.00
- Year High
- $66.66
- Year Low
- $9.63
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $30.79
Company Overview
NASDAQ
Peter Kent Hawryluk
Biotechnology
Healthcare
MBX
63
US
USD
Liquidity Metrics
0.00
30.79
30.79
3.10
0.00
Sales & Valuation
-$
0.00
6.60
-36.97
-1.71
Profitability
-$2.38
-$86.97M
0.00%
0.00%
-24.50%
-19.13%
P/E Metrics
-28.18
25.10
25.10
Analyst Price Target & Rating
$70.00
$90.00
$56.00
2/5
7 Analysts
-11.43%
Financial Health Scores
83.37
2/9
$433.97M
$452.7M
$14.94M
-$86.61M
Key Metrics (TTM)
$2.91B
0.00
-33.65
30.79
-24.50%
-22.54%
-3.00%
-2.70%
-11364 days
Company Executives
| Name | Title |
|---|---|
| Andreas Moraitis | Senior Vice President of Clinical Development |
| Mark R. Soued | Chief Commercial Officer |
| Karen Basbaum | Chief Business Officer |
| Steven L. Hoerter | Executive Chairperson |
| Michelle Graham | Chief Human Resources Officer |
| Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications |
| Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls |
| John W. Smither | Interim Chief Financial Officer |
| Michael A. Dorato DABT | Sr. Vice President of Discovery & Non-Clinical Development |
| Mark Hope | Senior Vice President of Regulatory & Quality |
| Salomon Azoulay | Chief Medical Officer |
| Peter Kent Hawryluk | Chief Executive Officer, President & Director |
Poll Results
No votes yet today — be the first to share your view!
About MBX Biosciences, Inc. Common Stock (NASDAQ:MBX) Stock
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291 ... , a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Why
2026-07-26 02:02:32
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $66.66 and last traded at $61.10, with a volume of 107404 shares trading hands. The stock had previously closed at $63.57. Analyst Ratings Changes A number of analysts have
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
2026-07-17 05:49:10
MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation. Valuation and Earnings This table compares MBX Biosciences
2026-07-13 16:15:00
CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoerter, current Executive Chairman of the Board, as its new Chairman and Chief Executive Officer. Mr. Hoerter succeeds Kent Hawryluk, who will step down as President, Chief Executive Officer and a member of the Board of Directors. In addition, the Board has appointed John Smither, current Interim Chief Financial Officer, as the Company's new Chief Financial Officer. All leadership changes are effective immediately.
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
2026-07-06 08:38:04
I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks.
2026-06-12 14:32:09
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
2026-06-12 10:43:54
MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism.
2026-06-12 07:00:00
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial
2026-06-01 08:00:00
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.
Frequently Asked Questions
-
What is the current MBX Biosciences, Inc. Common Stock (MBX) stock price?
-
MBX Biosciences, Inc. Common Stock(NASDAQ:MBX) stock price is $62 in the last trading session. During the trading session, MBX stock reached the peak price of $66.66 while $9.63 was the lowest point it dropped to. The percentage change in MBX stock occurred in the recent session was --2.47% while the dollar amount for the price change in MBX stock was -$1.57.
-
MBX's industry and sector of operation?
-
The NASDAQ listed MBX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MBX?
-
Andreas Moraitis | Senior Vice President of Clinical Development
Mark R. Soued | Chief Commercial Officer
Karen Basbaum | Chief Business Officer
Steven L. Hoerter | Executive Chairperson
Michelle Graham | Chief Human Resources Officer -
How many employees does MBX have?
-
Number of MBX employees currently stands at 63. MBX operates from 11711 N. Meridian Street, Carmel, IN 46032, US.
-
Link for MBX official website?
-
Official Website of MBX is: https://mbxbio.com
-
How do I contact MBX?
-
MBX could be contacted at phone #(317) 659-0200 and can also be accessed through its website. MBX operates from 11711 N. Meridian Street, Carmel, IN 46032, US.
-
How many shares of MBX are traded daily?
-
The average number of MBX shares traded daily for last 3 months was 857.07K.
-
What is the market cap of MBX currently?
-
The market value of MBX currently stands at $2.95B with its latest stock price at $62